State Street Corp cut its position in shares of Celgene Corporation (NASDAQ:CELG) by 0.2% in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 32,410,705 shares of the biopharmaceutical company’s stock after selling 62,712 shares during the quarter. State Street Corp owned approximately 4.14% of Celgene worth $4,209,186,000 at the end of the most recent quarter.
Several other hedge funds and other institutional investors have also recently modified their holdings of the company. Janus Henderson Group PLC lifted its position in Celgene by 4,290.5% during the second quarter. Janus Henderson Group PLC now owns 8,408,961 shares of the biopharmaceutical company’s stock valued at $1,092,071,000 after buying an additional 8,217,433 shares in the last quarter. BlackRock Inc. lifted its position in Celgene by 5.7% during the second quarter. BlackRock Inc. now owns 56,725,342 shares of the biopharmaceutical company’s stock valued at $7,366,919,000 after buying an additional 3,084,227 shares in the last quarter. Oaktop Capital Management II L.P. acquired a new position in Celgene during the second quarter valued at approximately $271,605,000. Vanguard Group Inc. lifted its position in Celgene by 3.1% during the second quarter. Vanguard Group Inc. now owns 53,527,210 shares of the biopharmaceutical company’s stock valued at $6,951,579,000 after buying an additional 1,610,056 shares in the last quarter. Finally, Harbour Capital Advisors LLC lifted its position in Celgene by 12,913.6% during the second quarter. Harbour Capital Advisors LLC now owns 1,587,271 shares of the biopharmaceutical company’s stock valued at $12,222,000 after buying an additional 1,575,074 shares in the last quarter. Institutional investors and hedge funds own 80.17% of the company’s stock.
In other Celgene news, Director Gilla Kaplan sold 9,250 shares of the company’s stock in a transaction dated Tuesday, September 12th. The shares were sold at an average price of $141.56, for a total value of $1,309,430.00. Following the completion of the sale, the director now directly owns 85,551 shares of the company’s stock, valued at approximately $12,110,599.56. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Terrie Curran sold 1,727 shares of the company’s stock in a transaction dated Monday, September 25th. The shares were sold at an average price of $143.89, for a total transaction of $248,498.03. Following the completion of the sale, the insider now directly owns 3,925 shares of the company’s stock, valued at $564,768.25. The disclosure for this sale can be found here. Corporate insiders own 0.95% of the company’s stock.
Celgene (NASDAQ:CELG) last announced its earnings results on Thursday, October 26th. The biopharmaceutical company reported $1.91 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $1.87 by $0.04. The firm had revenue of $3.29 billion during the quarter, compared to analyst estimates of $3.42 billion. Celgene had a net margin of 27.36% and a return on equity of 63.80%. Celgene’s revenue was up 10.2% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $1.58 EPS. equities analysts forecast that Celgene Corporation will post 6.67 earnings per share for the current fiscal year.
A number of research analysts have recently commented on CELG shares. Vetr raised shares of Celgene from a “buy” rating to a “strong-buy” rating and set a $148.32 target price on the stock in a research report on Wednesday, August 16th. Cantor Fitzgerald reissued a “buy” rating and set a $162.00 target price on shares of Celgene in a research report on Tuesday, September 26th. Atlantic Securities raised shares of Celgene from a “neutral” rating to an “overweight” rating in a research report on Friday. Piper Jaffray Companies reissued a “neutral” rating and set a $133.00 target price on shares of Celgene in a research report on Monday, October 23rd. Finally, Stifel Nicolaus cut their price target on shares of Celgene from $155.00 to $149.00 and set a “buy” rating on the stock in a report on Friday, October 20th. One research analyst has rated the stock with a sell rating, eleven have given a hold rating, twenty have issued a buy rating and two have assigned a strong buy rating to the company. The company has an average rating of “Buy” and an average target price of $139.57.
ILLEGAL ACTIVITY WARNING: This news story was reported by Sports Perspectives and is the sole property of of Sports Perspectives. If you are accessing this news story on another publication, it was copied illegally and reposted in violation of international trademark and copyright laws. The legal version of this news story can be read at https://sportsperspectives.com/2017/12/09/state-street-corp-sells-62712-shares-of-celgene-corporation-celg.html.
Celgene Company Profile
Celgene Corporation is an integrated global biopharmaceutical company. The Company, together with its subsidiaries, is engaged in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases through solutions in protein homeostasis, immuno-oncology, epigenetics, immunology and neuro-inflammation.
Want to see what other hedge funds are holding CELG? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Celgene Corporation (NASDAQ:CELG).
Receive News & Ratings for Celgene Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celgene Corporation and related companies with MarketBeat.com's FREE daily email newsletter.